Shareholders' Deficit (Details Textual) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 08, 2020 |
Apr. 17, 2020 |
Apr. 02, 2020 |
Jan. 13, 2020 |
Dec. 12, 2019 |
Apr. 28, 2020 |
Feb. 20, 2020 |
Feb. 18, 2020 |
Nov. 30, 2019 |
Oct. 31, 2019 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Jun. 30, 2019 |
Jun. 30, 2020 |
Jun. 30, 2019 |
Dec. 31, 2019 |
|
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Preferred Stock par value | $ 0.10 | $ 0.10 | $ 0.10 | |||||||||||||
| Net of fees | $ 1,750 | |||||||||||||||
| Amortization of debt discount | 305,438 | $ 14,142 | ||||||||||||||
| Accrued interest | $ 28,085 | $ 28,085 | ||||||||||||||
| Common shares issued for debt conversion, shares | 203,125 | 13,275,000 | ||||||||||||||
| Amount of common stock upon conversion | 91,365 | |||||||||||||||
| Accrued dividends | 1,195 | $ 1,195 | ||||||||||||||
| Stock-based compensation | 287,587 | 1,429,167 | ||||||||||||||
| Unaccreted debt discount | $ 1,864 | |||||||||||||||
| Interest expense | 216,378 | $ 60,105 | 457,581 | 112,639 | ||||||||||||
| Issuance of common shares for services, amount | $ 50,000 | 50,000 | ||||||||||||||
| Stock-based professional fees | (45,000) | (235,042) | ||||||||||||||
| Total unrecognized compensation expense related to unvested common shares | 279,127 | $ 279,127 | ||||||||||||||
| Weighted average period | 1 year | |||||||||||||||
| Aggregate principal amount | 356,938 | $ 356,938 | $ 135,833 | |||||||||||||
| Convert of deferred compensation | $ 16,250 | |||||||||||||||
| Exercise of stock options, value | 19,185 | |||||||||||||||
| Recorded settlement expense | ||||||||||||||||
| Increase decrease in accounts payable | 211,741 | 189,861 | ||||||||||||||
| Increase decrease in accrued expenses | 78,045 | 28,371 | ||||||||||||||
| Shares issued for deferred compensation, description | The Company entered into two one-year advisory board agreements with two individuals for services to be rendered on the Company's medical advisory board. In connection with these advisory board agreements, the Company issued an aggregate of 500,000 restricted common shares of the Company to these advisory board members. These shares vest on April 1, 2021. These shares were valued at $20,000, or $0.04 per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement, during the six months ended June 30, 2020, accretion of stock-based consulting fees amounted to $5,000 and the remaining stock-based consulting fees of $15,000 shall be accreted over the remaining vesting period. | |||||||||||||||
| Conversion of principal balance | $ 74,250 | |||||||||||||||
| Stock option, description | The weighted average period over which stock-based compensation expense related to these options will be recognized is approximately 4 months. | |||||||||||||||
| Accrued dividend payable | $ 4,123 | |||||||||||||||
| Equity Option [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Recognized compensation expense | 382,615 | $ 1,042,506 | ||||||||||||||
| Total unrecognized compensation expense related to unvested common shares | 227,046 | 227,046 | ||||||||||||||
| Accounts Payable [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Common shares per share | $ 0.04 | |||||||||||||||
| Sale of common shares, shares | 151,456 | |||||||||||||||
| Sale of common shares, value | $ 6,058 | |||||||||||||||
| Consulting Agreement [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Common shares per share | $ 0.04 | |||||||||||||||
| Shares of grant restricted stock award of common shares | 1,250,000 | |||||||||||||||
| Value of grant restricted stock award of common shares | $ 50,000 | |||||||||||||||
| Stock-based professional fees | 33,333 | |||||||||||||||
| Prepaid expenses | $ 16,667 | $ 16,667 | ||||||||||||||
| Employment Agreements [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Common shares per share | $ 0.04 | |||||||||||||||
| Shares of grant restricted stock award of common shares | 200,000 | |||||||||||||||
| Value of grant restricted stock award of common shares | $ 8,000 | |||||||||||||||
| Restricted Stock Award Agreements [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Common shares per share | $ 0.04 | |||||||||||||||
| Shares of grant restricted stock award of common shares | 6,750,000 | |||||||||||||||
| Value of grant restricted stock award of common shares | $ 270,000 | |||||||||||||||
| Percentage of restricted shares | 100.00% | |||||||||||||||
| Investor [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Common shares per share | $ 0.023 | $ 0.04 | $ 0.04 | |||||||||||||
| Sale of common shares, shares | 7,000,000 | 7,000,000 | 7,000,000 | |||||||||||||
| Sale of common shares, value | $ 161,000 | $ 280,000 | $ 280,000 | |||||||||||||
| Warrants [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Exercise price | $ 0.10 | $ 0.10 | ||||||||||||||
| Warrant exercise price reduced | $ 0.003 | $ 0.003 | ||||||||||||||
| Warrant purchase, description | On March 30, 2020 and on April 23, 2020, in connection with Purchase Agreements with an accredited investor (See Note 6), the Company issued warrants to purchase an aggregate amount up to 288,750 shares of the Company's common stock (the "Warrants"). The Warrants are exercisable at any time on or after the date of the issuance and entitles this investor to purchase shares of the Company's common stock for a period of five years from the initial date the warrants become exercisable. Under the terms of the Warrants, the holder is entitled to exercise the Warrants to purchase up to 288,750 shares of the Company's common stock at an initial exercise price of $0.10, subject to adjustment as detailed in the Warrants. In connection with the issuance of the warrants, on the initial measurement date, the relative fair value of the warrants of $14,498 was recorded as a debt discount and an increase in paid-in capital (See Note 6). | |||||||||||||||
| 2018 Long-term Incentive Plan [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Aggregate shares of common stock issued without any minimum vesting period | 25,000,000 | |||||||||||||||
| Aggregate number of common stock issued under plan | 50,000,000 | |||||||||||||||
| Incentive stock options | 11,445,698 | 11,445,698 | ||||||||||||||
| Description of options to acquire common stock | The exercise price of options granted under our 2018 Plan must at least be equal to the fair market value of the Company's common stock on the date of grant and the term of an option may not exceed ten years, except that with respect to an incentive stock option granted to any employee who owns more than 10% of the voting power of all classes of the Company's outstanding stock as of the grant date the term must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. | |||||||||||||||
| Restricted stock have been issued | $ 22,700,000 | $ 22,700,000 | ||||||||||||||
| Series A Preferred Stock [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Shares designated | 800,000 | 800,000 | 800,000 | |||||||||||||
| Preferred Stock par value | $ 0.10 | $ 0.10 | $ 0.10 | $ 0.10 | $ 0.10 | |||||||||||
| Preferred stock stated value | $ 1.00 | $ 1.00 | ||||||||||||||
| Preferred Stock dividend Rate | 4.00% | |||||||||||||||
| Preferred stock dividend increased | 22.00% | |||||||||||||||
| Conversion price converted into market price | 81.00% | |||||||||||||||
| Market price representing at discount rate | 19.00% | |||||||||||||||
| Debt premium charge to interest expenses | $ 42,553 | |||||||||||||||
| Preferred stock unregistered | 159,600 | 159,600 | 154,800 | 154,800 | ||||||||||||
| Preferred stock unregistered value | $ 133,000 | $ 133,000 | $ 129,000 | $ 129,000 | ||||||||||||
| Cash proceeds | 127,000 | 127,000 | 120,000 | |||||||||||||
| Net of fees | 6,000 | 6,000 | 9,000 | |||||||||||||
| Amortization of debt discount | $ 6,000 | $ 6,000 | 9,000 | |||||||||||||
| Amortization of discount charged to interest expense | 10,083 | |||||||||||||||
| Accrued interest | 1,864 | 1,864 | ||||||||||||||
| Debt premium to paid-in capital. | 37,438 | 37,438 | ||||||||||||||
| Stated value | $ 159,600 | 159,600 | ||||||||||||||
| Amount of common stock upon conversion | $ 159,600 | |||||||||||||||
| Shares of common stock upon conversion | 9,982,616 | |||||||||||||||
| Common shares per share | $ 0.833 | $ 0.833 | $ 0.833 | $ 0.833 | ||||||||||||
| Accrued dividends | $ 3,192 | $ 3,192 | ||||||||||||||
| Series A preferred stock balance | 176,543 | 176,543 | ||||||||||||||
| Liquidation value | 154,800 | 154,800 | ||||||||||||||
| Aggregate premium | 36,312 | 36,312 | ||||||||||||||
| Unaccreted debt discount | 12,183 | 12,183 | ||||||||||||||
| Unamortized debt offering costs | $ 4,250 | 4,250 | ||||||||||||||
| Interest expense | $ 96,976 | |||||||||||||||
| Description of options to acquire common stock | The Company issued 9,982,616 shares its common stock upon the conversion of 159,600 shares of Series A preferred with a stated redemption value of $159,600 and related accrued dividends payable of $3,192. The conversion price was based on contractual terms of the related Series A preferred shares. Upon conversion, the Company reclassified put premium of $37,438 to paid-in capital. | |||||||||||||||
| Series B Preferred Stock [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Shares designated | 100,000 | 100,000 | 100,000 | 100,000 | ||||||||||||
| Preferred Stock par value | $ 0.10 | $ 0.10 | $ 0.10 | $ 0.10 | ||||||||||||
| Preferred Stock dividend Rate | 2.00% | |||||||||||||||
| Stated value | $ 1,000 | |||||||||||||||
| Accrued dividends | $ 108,000 | $ 1,195 | $ 1,195 | |||||||||||||
| Liquidation value | $ 108,000 | 108,000 | ||||||||||||||
| Conversion of principal balance | $ 109,195 | |||||||||||||||
| Stock option, description | The Series B is convertible at the option of a holder or if the closing price of the common stock exceeds 400% of the Conversion Price for a period of twenty consecutive trading days, at the option of the Company. Conversion Price means a price per share of the common stock equal to 100% of the lowest daily volume weighted average price of the common stock during the two years preceding or subsequent two years following the Issuance Date, subject to adjustment as otherwise provided in the Certificate of Designations (the "Conversion Price"). | |||||||||||||||
| Convertible Preferred Stock [Member] | ||||||||||||||||
| Shareholders' Deficit (Textual) | ||||||||||||||||
| Settlement of accrued compensation | 108 | |||||||||||||||